The flu shot in your arm this autumn was chosen last winter. About six months before a season begins, a global network of laboratories decides which influenza viruses manufacturers will grow and bottle, and it makes that call while the actual season is still an open question. Everything downstream, including whether a season is later called a good match or a poor one, flows from that early bet against a moving target.
Key points#
- Flu vaccine composition is decided roughly six months in advance because most vaccine is still grown in eggs, which takes months to scale.
- Laboratories choose strains by measurement, comparing how well antibodies against candidate viruses recognize what is actually circulating.
- Antigenic drift, the slow accumulation of mutations in the virus surface proteins, is why the vaccine has to be updated almost every year and why a mismatch can appear after the recipe is locked.
- A "low-effectiveness" season usually means reduced protection against getting sick, not zero benefit, and protection against severe illness tends to hold up better.
Why the timing forces an early guess#
Start with the constraint that shapes everything else: manufacturing lead time. Most influenza vaccine is still produced in fertilized chicken eggs, a method that cannot be rushed. To have hundreds of millions of doses ready before winter, the recipe has to be fixed months earlier, long before anyone can see which virus will dominate.
That is why the recommendation is issued twice a year rather than once. The World Health Organization convenes experts each February for the Northern Hemisphere and each September for the Southern Hemisphere, because the two halves of the globe have opposite winters and need vaccines on opposite schedules. For the 2026-2027 Northern Hemisphere season, the WHO published its recommendation on 27 February 2026, naming an A/Missouri/11/2025 (H1N1)pdm09-like virus, an A/Darwin/1454/2025 (H3N2)-like virus, and a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus. Most seasonal vaccines are now trivalent, covering two influenza A subtypes and one B lineage, after the B/Yamagata lineage stopped circulating and was removed.
How the strains are actually chosen#
The decision behind those names is closer to laboratory measurement than to prediction. The Global Influenza Surveillance and Response System, a worldwide network of national laboratories and WHO Collaborating Centres, samples circulating viruses all year. The central question each cycle is simple to state: does last season's vaccine virus still resemble what is spreading now?
To answer it, laboratories perform antigenic characterization. They raise antibodies against the vaccine virus and test how well those antibodies recognize freshly collected viruses. The reference reagent is post-infection ferret antiserum. Ferrets are used because their respiratory response to human influenza tracks ours closely, and their antisera pick up small surface changes with high sensitivity.
The classic assay is hemagglutination inhibition, which measures how strongly the antibodies block a virus from clumping red blood cells. When newly collected viruses react weakly against antiserum raised to the current vaccine strain, that weak reaction is the signal of antigenic distance. By long convention, a drop of roughly fourfold or more is treated as meaningful, a deliberate threshold that avoids swapping strains over differences too small to matter for patients. Genetic sequencing of the hemagglutinin gene runs in parallel, so the evolutionary and antibody signals are read side by side.
Antigenic drift: the reason the match varies#
Influenza's two surface proteins, hemagglutinin and neuraminidase, absorb a constant trickle of point mutations. Antibodies from prior infection and vaccination push back, so variants that partly slip past that immunity spread more easily than their neighbors. This slow reshaping is antigenic drift, and it is the core reason a new formulation is needed almost every year.
The problem is one of timing rather than science. A drifted variant can rise to dominance after the recipe is set and the eggs are already inoculated, leaving no way to adjust. Writing in the New England Journal of Medicine after the severe 2003-2004 season, John Treanor described exactly this trap: an antigenically variant H3N2 virus, A/Fujian/411/2002, took off after that year's strain had been chosen, producing a notable mismatch.
The 2025-2026 season rehearsed the same pattern. An H3N2 subclade, informally called subclade K, spread widely while sitting well apart from the H3N2 virus in the vaccine, and ferret antisera against the season's strains showed reduced reactivity to it. Interim estimates put protection against H3N2 illness in the modest range for adults, with higher figures in children. The mechanism here is drift, not the more dramatic "shift" that produces pandemics. Drift is gradual and expected, and it is exactly what the routine annual update is designed to chase.
How to read a "low-effectiveness" season#
A mismatch lowers effectiveness; it rarely erases it. Two ideas make the headline numbers easier for you to interpret.
First, what is being measured changes the number dramatically. A vaccine can look far more effective against laboratory-confirmed influenza than against "all respiratory illness," simply because most winter respiratory illness is not influenza at all. A low percentage against every sniffle is not the same as a low percentage against the flu itself.
Second, the type of protection matters. Defense against severe outcomes such as hospitalization often holds up better than defense against milder infection, even in a drifted year. The US Centers for Disease Control and Prevention notes that closer matches tend to produce stronger protection, and that even when circulating viruses are quite different, vaccination can still cut risk by as much as 30 percent.
Put together, a season labeled "low effectiveness" usually means a smaller reduction in your chance of getting sick, not the absence of benefit, and the benefit is generally largest where it counts most. That is why public health authorities keep recommending annual vaccination even when a perfect match cannot be promised: the downside of a drifted season is usually a thinner benefit rather than none. The distinction is easy to lose when a single number travels through the news.
Sources and further reading
Questions and answers
Why not just wait and see which strain circulates before making the vaccine?
Because manufacturing cannot keep pace with the season. Growing enough egg-based vaccine takes months, so the recipe must be locked long before the first cases appear. Waiting would mean no vaccine ready when it is needed.
Does a mismatched year mean the flu shot was useless?
No. A mismatch usually reduces protection against getting sick rather than eliminating it, and protection against hospitalization and severe illness tends to hold up better than protection against milder infection.
What is the difference between antigenic drift and shift?
Drift is the slow accumulation of small mutations that lets the virus partly escape existing immunity, and it is why the vaccine is updated most years. Shift is a larger, abrupt change that can produce a virus most people have no immunity to, the kind of event associated with pandemics.